“The upcoming budget could bring positive changes for consumers, boosting sales in India. In the life sciences sector, 2024 holds promise with new treatments, more use of AI, and more mergers. A recent report from Boston Consulting Group (BCG) and B Capital highlights the potential, with the digital healthcare sector expected to leap from $2.7 billion in 2022 to about $37 billion by 2030.
Truemeds, which focuses on affordable substitute medicines, is eagerly waiting for budget policies that support fair competition and keep medicines affordable for everyone. As we know, Janaushadhi Kendras emerged as a game-changer, amplifying access to affordable substitute medicines. Truemeds is aligning with this vision to foresee transformative shifts in the pharmaceutical landscape. Together we want to pioneer budget-friendly healthcare solutions for all, fostering a healthier and more inclusive future.
As we navigate the uncertainties of the pharmaceutical landscape, Truemeds stands ready to embrace opportunities and contribute to the industry’s growth story. Delving into the details of the budget, we also acknowledge the critical aspect of essential medicines taxation and its impact on prices. On a more relatable note, the escalating cost of medicines poses a significant burden on the average chronic or diabetes patient in India, highlighting the urgency for budgetary measures to address this issue. As we await further details from the budget, these preliminary insights provide a glimpse into the potential opportunities and challenges ahead. We’re ready to be part of the industry’s growth, waiting for more details from the budget.”
